Leitlinien zur postexpositionellen Prophylaxe der HIV-Infektion

Planning, Policy, and Prediction. New York: Raven; 1994: 423-38.
Postexpositionelle Prophylaxe der HIV-Infektion
(77) WILEY JA, HERSCHKORN SJ, PADIAN NS. Heterogeneity in the probability of HIV transmission
per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse. Statistics in
Medicine 1989; 8: 93-102.
(78) LIFSON AR, O'MALLEY PM, HESSOL NA, BUCHBINDER SP, CANNON L, RUTHERFORD GW.
HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation:
implications for counseling concerning safe sexual practices. Am J Public Health 1990; 80: 1509-1511.
(79) AUVERT B, TALJAARD D LAGARDE E, SOBNGWI-TAMBEKOU J, SITTA R, PUREN A:
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the
ANRS 1265 trial. PLos Medicine 2005; 2: 1112-22
(80) Gray R et al. Male Circumcision for HIV Prevention in men in Rakai, Uganda: a randomised trial. The
Lancet, Vol 369 February 24, 2007
(81) Bailey R et al., Male Circumcision for HIV Prevention in young men in Kisumu, Kenya: a randomised
controlled trial, The Lancet, Vol 369 February 24, 2007
(82) PILCHER CD, TIEN HC, ERON JJ, VERNAZZA PL, LEU S_Y, STEWART PW, GOH L-E, COHEN
MS, ET AL.: Brief but efficient: Acute HIV infection and the sexual transmission of HIV. J Inf Dis
2004; 189:1785-92
(83) DEL ROMERO J, MARINCOVICH B, CASTILLA J, et al. Evaluating the risk of HIV transmission
through unprotected orogenital sex. AIDS 2002; 19: 1296-97
(84) BORNEMANN R: Needle sharing, in: JÖRG GÖLZ (Hrsg.): Moderne Suchtmedizin, Thieme 1999,
Kap. C 3.6.4, S.1-4
(85) KAPLAN EH, HEIMER R . A model-based estimate of HIV infectivity via needle sharing. J Acquir
Immune Defic Syndr 1992; 5: 1116-1118.
(86) MONTELLA F, DI SORA F, RECCHIA O. Can HIV-1 infection be transmitted by a "discarded"
syringe? Journal of Acquired Immune Deficiency Syndrome 1992; 5: 1274-1275.
(87) RUSSELL FM, NASH MC: A prospective study of children with community-acquired needlestick injuries
in Melbourne. J Paediatr Child Health 2002; 38: 321-323.
(88) DERDELINCKX I, WAINBERG MA, LANGE JMA, HILL A; HALIMA J, BOUCHER CAB: Criteria for drugs
used in pre-exposure prophylaxis trials against HIV infection. PLoS Medicine 2006; 3: 1999-2004
(89) BALZARINI J, VAN HERREWEGE Y, VANHAM G: Metabolic activation of nucleoside and
nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 2002; 16: 2159-2163
(90) HENEINE W: Chemoprophylaxis with antiretrovirals in monkey models. 1 st International Workshop on
HIV transmission. Toronto, 2006
(91) BASSETT IV, FREEDBERG KA, WALENSKY RP: Two drugs or three? Balancing efficacy, toxicity, and
resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Inf Dis 2004; 39: 395-
401
(92) RABAUD C, BURTY C, VALLE C, et al.: Post-exposure prophylaxis of HIV infection: comparison of
the tolerability of 3 PEP regimens. Abstr. TuPeB4651, Internat. AIDS-Konferenz 2004, Bangkok
(93) WINSTON A, MCALLISTER J, AMIN J, COOPER DA, CARR A: The use of a triple nucleosidenucleotide
regimen for nonoccupational HIV post-exposure prophylaxis. HIV Medicine 2005; 6: 191-7
(94) MAYER KH, MIMIAGA MJ, COHEN D, et al.: Tenofovir-based regimens for non-occupational exposure
prophylaxis: improved tolerability and adherence compared to AZT-based regimens. Abstr. 21, 1 st
International Workshop on HIV transmission. Toronto, 2006 Rev Antir Ther 2006; 4: 34
(95) PAVEL S, BURTY C, ALCARAZ I, et al.: Severe liver toxicity in postexposure prophylaxis for HIV
infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS 2007; 21: 268-9
(96) PANEL ON CLINICAL PRACTICES FOR TREATMENT OF HIV INFECTION. Guidelines for the
use of antiretroviral agents in HIV-infected adults and adolescents. Available at
.
38